Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas, F
Miranda Rota, E
Ben Aissa, A
Werner Sunderland, M
Melanoma TRACERx Consortium
Renal TRACERx Consortium
Lung TRACERx Consortium
MetadataShow full item record
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We demonstrated that CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans. While existing anti-CD25 antibodies were observed to deplete Treg cells in the periphery, upregulation of the inhibitory Fc gamma receptor (FcγR) IIb at the tumor site prevented intra-tumoral Treg cell depletion, which may underlie the lack of anti-tumor activity previously observed in pre-clinical models. Use of an anti-CD25 antibody with enhanced binding to activating FcγRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Treg cell ratios, and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies promoted complete tumor rejection, demonstrating the relevance of CD25 as a therapeutic target and promising substrate for future combination approaches in immune-oncology.
Version of record
Fc gamma receptors
inhibitory Fc receptor
regulatory T cells
Cell Line, Tumor
Immunoglobulin Fc Fragments
Interleukin-2 Receptor alpha Subunit
Programmed Cell Death 1 Receptor
Melanoma and Kidney Cancer
License start date
Immunity, 2017, 46 (4), pp. 577 - 586
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Genome-wide characterization reveals complex interplay between TP53 and TP63 in response to genotoxic stress. McDade, SS; Patel, D; Moran, M; Campbell, J; Fenwick, K; Kozarewa, I; Orr, NJ; Lord, CJ; Ashworth, AA; McCance, DJ (2014-06)In response to genotoxic stress the TP53 tumour suppressor activates target gene expression to induce cell cycle arrest or apoptosis depending on the extent of DNA damage. These canonical activities can be repressed by ...
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. Natrajan, R; Wilkerson, PM; Marchiò, C; Piscuoglio, S; Ng, CK; Wai, P; Lambros, MB; Samartzis, EP; Dedes, KJ; Frankum, J; Bajrami, I; Kopec, A; Mackay, A; A'hern, R; Fenwick, K; Kozarewa, I; Hakas, J; Mitsopoulos, C; Hardisson, D; Lord, CJ; Kumar-Sinha, C; Ashworth, A; Weigelt, B; Sapino, A; Chinnaiyan, AM; Maher, CA; Reis-Filho, JS (2014-04)Micropapillary carcinoma (MPC) is a rare histological special type of breast cancer, characterized by an aggressive clinical behaviour and a pattern of copy number aberrations (CNAs) distinct from that of grade- and oestrogen ...
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. Hrebien, S; O'Leary, B; Beaney, M; Schiavon, G; Fribbens, C; Bhambra, A; Johnson, R; Garcia-Murillas, I; Turner, N (2016)Circulating tumor DNA (ctDNA) analysis has the potential to allow non-invasive analysis of tumor mutations in advanced cancer. In this study we assessed the reproducibility of digital PCR (dPCR) assays of circulating tumor ...